Cisplatin-induced cardiotoxicity– two case reports

Author(s): Sawant J, Prakruthi AD, Daddi J, Ghosh A, Joshi A, et al.


Cisplatin has been used for over 40 years in various cancer chemotherapies. Toxicity induced by cisplatin-based therapeutic regimens include gastrointestinal toxicity, myelotoxicity, neurotoxicity, ototoxicity and nephrotoxicity. Cisplatin-based regimens have been associated with a wide range of cardiovascular complications. In this paper, we report 2 cases of cisplatin-induced cardiotoxicity. We present cases of 2 young patients who developed acute myocardial infarction during combination chemotherapy with bleomycin, etoposide and cisplatin. The first patient had acute anterior wall ST elevation myocardial infarction and the second one had acute myocardial infarction with peripheral arterial thromboembolism. Cisplatin use can result in cardiovascular events. Clinicians should be very cautious while managing patients on cisplatin-based chemotherapy. Early recognition of cardiotoxicity will allow for timely prevention of permanent cardiac damage.

Similar Articles

Acute aortic thrombosis in patients receiving cisplatin-based chemotherapy

Author(s): Fernandes DD, Louzada ML, Souza CA, Matzinger F

Cardiotoxicity of cytotoxic drugs

Author(s): Schimmel K, Richel D, Van-Den BRB, Guchelaar HJ

Lung cancer as a cardiotoxic state:a rewiev

Author(s): Pérez-Callejo D, Torrente M, Brenes MA, Núñez B, Provencio M

Characterization of cardiovascular alterations induced by different chronic cisplatin treatments

Author(s): Herradón E, González C, Uranga JA, Abalo R, Martín MI, et al.

Cardiovascular morbidity in long-term survivors of metastatic testicular cancer

Author(s): Meinardi MT, Gietema JA, Van-der GWT, Van-Veldhuisen DJ, Runne MA, et al.

Cardiovascular toxicity induced by chemotherapy,targeted agents and radiotherapy: ESMO Clinical Practice Guidelines

Author(s): Curigliano G, Cardinale D, Suter T , Plataniotis G, De Azambuja E, et al.